Your browser doesn't support javascript.
loading
A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor-positive disease.
Storr, Sarah J; Hoskin, Victoria; Aiyappa-Maudsley, Radhika; Ghaffari, Abdi; Varma, Sonal; Green, Andrew; Rakha, Emad; Ellis, Ian O; Greer, Peter A; Martin, Stewart G.
Afiliación
  • Storr SJ; Nottingham Breast Cancer Research Centre, Biodiscovery Institute, University of Nottingham, School of Medicine, Nottingham, UK.
  • Hoskin V; Division of Cancer Biology and Genetics, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada.
  • Aiyappa-Maudsley R; Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
  • Ghaffari A; Nottingham Breast Cancer Research Centre, Biodiscovery Institute, University of Nottingham, School of Medicine, Nottingham, UK.
  • Varma S; Division of Cancer Biology and Genetics, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada.
  • Green A; Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
  • Rakha E; Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
  • Ellis IO; Nottingham Breast Cancer Research Centre, Biodiscovery Institute, University of Nottingham, School of Medicine, Nottingham, UK.
  • Greer PA; Nottingham Breast Cancer Research Centre, Biodiscovery Institute, University of Nottingham, School of Medicine, Nottingham, UK.
  • Martin SG; Nottingham Breast Cancer Research Centre, Biodiscovery Institute, University of Nottingham, School of Medicine, Nottingham, UK.
Cancer Med ; 12(9): 10908-10916, 2023 05.
Article en En | MEDLINE | ID: mdl-36938826
INTRODUCTION: The cytoskeletal protein ezrin is upregulated in many cancer types and is strongly associated with poor patient outcome. While the clinical and prognostic value of ezrin has been previously evaluated in breast cancer, most studies to date have been conducted in smaller cohorts (less than 500 cases) or have focused on specific disease characteristics. The current study is the largest of its kind to evaluate ezrin both at the protein and mRNA levels in early-stage breast cancer patients using the Nottingham (n = 1094) and METABRIC (n = 1980) cohorts, respectively. RESULTS: High expression of ezrin was significantly associated with larger tumour size (p = 0.027), higher tumour grade (p < 0.001), worse Nottingham Prognostic Index prognostic group (p = 0.011) and HER2-positive status (p = 0.001). High ezrin expression was significantly associated with adverse survival of breast cancer patients (p < 0.001) and remained associated with survival in multivariate Cox-regression analysis (p = 0.018, hazard ratio (HR) = 1.343, 95% confidence interval (CI) = 1.051-1.716) when potentially confounding factors were included. High ezrin expression was significantly associated with adverse survival of patients whose tumours were categorised as receptor (oestrogen receptor (ER), progesterone receptor (PgR) or HER2) positive (p < 0.001) in comparison to those categorised as triple-negative breast cancer (p = 0.889). High expression of ezrin mRNA (VIL2) in the METABRIC cohort was also significantly associated with adverse survival of breast cancer patients (p < 0.001). CONCLUSION: Retrospective analyses show that ezrin is an independent prognostic marker, with higher expression associated with shortened survival in receptor-positive (ER, PgR or HER2) patients. Ezrin expression is associated with more aggressive disease and may have clinical utility as a biomarker of patient prognosis in early-stage breast cancer.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos